Compared with VEGF levels in the control tumours, gefitinib alone tended to decrease VEGF concentration (P=0.157), whereas AZD2171 alone enhanced levels of VEGF in the tumour (P=0.02 vs control). This evidence concerns the gene VEGFA and neoplasm.